According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

The smart inhalers market is experiencing significant growth, driven by the increasing incidence of respiratory diseases like asthma and COPD, techno ...

Merck’s MRK shares have lost 21.3% so far this year compared with a decrease of 4.5% for the industry. The stock has also ...

LONDON, GREATER LONDON, UNITED KINGDOM, May 23, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

The approval of ATZUMI and BREKIYA is expected to significantly reshape the migraine market by introducing new, innovative treatment options.

The shortfall for the Horizon products came during a quarter in which most of the company’s other treatments exceeded expectations. In fact, Amgen’s overall revenue of $8.1 billion was a 9% ...

Overall, total sales of Ozempic and Wegovy were around DKK 53.7 billion in Q4 2024, an increase of 35.4% year-on-year. The second advantage of Amgen's product ... of the combination of Lumakras ...

THOUSAND OAKS, Calif., Jan. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 4, 2025, after ...

Amgen's strong ... In their Q3 2024 financial report, the company showed 24% revenue year-over-year sales revenue growth (see image below), with 10 products delivering revenues above $1 billion ...

The NDA, which was completed in October 2024 ... alone or in combination with defactinib was also granted Orphan Drug Designation by the FDA for the treatment of LGSOC. Verastem Oncology has ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024 ... here) Amgen Inc. (NASDAQ:AMGN) develops and delivers human therapeutics globally. Its key products address ...

The NDA, which was completed in October 2024, has been granted ... a clinical collaboration with Amgen to evaluate LUMAKRAS™ (sotorasib) in combination with avutometinib and defactinib in ...